In this particular study, treatment-related mortality occurred in 5.3% and 1.6% of patients receiving irinotecan weekly and every three weeks, respectively. Determining a patient's genotype status ...

“The Braftovi regimen is emerging as a new standard of ... fluorouracil, oxaliplatin and irinotecan), or CAPOX (capecitabine ...

NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the ...